BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16868990)

  • 1. Are we coming to terms with tumor necrosis factor inhibition in pregnancy?
    Salmon JE; Alpert D
    Arthritis Rheum; 2006 Aug; 54(8):2353-5. PubMed ID: 16868990
    [No Abstract]   [Full Text] [Related]  

  • 2. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
    Rosner I; Haddad A; Boulman N; Feld J; Avshovich N; Slobodin G; Rozenbaum M
    Rheumatology (Oxford); 2007 Sep; 46(9):1508; author reply 1508-9. PubMed ID: 17684027
    [No Abstract]   [Full Text] [Related]  

  • 3. Rheumatoid arthritis and reproduction.
    Golding A; Haque UJ; Giles JT
    Rheum Dis Clin North Am; 2007 May; 33(2):319-43, vi-vii. PubMed ID: 17499710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recommendations of the German Society of Rheumatology for therapy with tumor necrosis factor inhibitors. Pharmacotherapy Committee of the German Society of Rheumatology].
    Z Rheumatol; 2000 Aug; 59(4):291-2. PubMed ID: 11013988
    [No Abstract]   [Full Text] [Related]  

  • 5. Maintaining and optimising anti-TNF therapy.
    Somerville M
    Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
    [No Abstract]   [Full Text] [Related]  

  • 6. Rheumatoid arthritis in pregnancy: successful outcome with anti-TNF agent (Etanercept).
    Sinha A; Patient C
    J Obstet Gynaecol; 2006 Oct; 26(7):689-91. PubMed ID: 17071443
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
    Haraoui B
    J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
    [No Abstract]   [Full Text] [Related]  

  • 8. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register.
    Hyrich KL; Symmons DP; Watson KD; Silman AJ;
    Arthritis Rheum; 2006 Aug; 54(8):2701-2. PubMed ID: 16871549
    [No Abstract]   [Full Text] [Related]  

  • 9. The British Society for Rheumatology Biologics Register: 6 years on.
    Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
    Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
    [No Abstract]   [Full Text] [Related]  

  • 10. Pregnancy in a rheumatoid arthritis patient on infliximab and methotrexate.
    Kinder AJ; Edwards J; Samanta A; Nichol F
    Rheumatology (Oxford); 2004 Sep; 43(9):1195-6. PubMed ID: 15317958
    [No Abstract]   [Full Text] [Related]  

  • 11. Tuberculosis in the cytokine era: what rheumatologists need to know.
    Hamilton CD
    Arthritis Rheum; 2003 Aug; 48(8):2085-91. PubMed ID: 12905459
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 13. Fibromyalgia in between: where do the musculoskeletal physicians and psychiatrists stand?
    Algül A; Basoglu C; Kiralp MZ; Ozçakar L
    Acta Reumatol Port; 2008; 33(4):477-8. PubMed ID: 19107094
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug insight: Anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation.
    Skomsvoll JF; Wallenius M; Koksvik HS; Rødevand E; Salvesen KA; Spigset O; Kvien TK
    Nat Clin Pract Rheumatol; 2007 Mar; 3(3):156-64. PubMed ID: 17334338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
    Kavanaugh A
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
    [No Abstract]   [Full Text] [Related]  

  • 16. Do all drugs and treatments for rheumatoid arthritis have the same efficacy?
    Weisman MH
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):298-9. PubMed ID: 18431369
    [No Abstract]   [Full Text] [Related]  

  • 17. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
    Kavanaugh A; Cohen S; Cush JJ
    J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
    [No Abstract]   [Full Text] [Related]  

  • 18. [Guidelines in RA treatment: concepts on safety and recommendations using anti-TNF-alpha inhibitors. Grupo de Estudio de Nuevas Terapias de Enfermedades reumáticas (GENTE)].
    Díaz-Jouanen E; Abud-Mendoza C; Garza-Elizondo MA; Medrano-Ramírez G; Burgos-Vargas R; Orozco-Alcalá JJ; Pacheco-Tena CF; Pineda C; Pozos-Espíndola JC; Ramos-Niembro F; Robles-San-Román M; Santana-Sahagún JE;
    Rev Invest Clin; 2009; 61(3):252-66. PubMed ID: 19736814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures.
    Wendling D; Balblanc JC; Brousse A; Lohse A; Lehuede G; Garbuio P; Toussirot E; Auge B; Jacques D
    Ann Rheum Dis; 2005 Sep; 64(9):1378-9. PubMed ID: 16100348
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus.
    Finucane KA; Archer CB
    Clin Exp Dermatol; 2005 Mar; 30(2):201-4. PubMed ID: 15725261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.